BridgeMD
New treatment option for Liver Transplantation
Official title APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor
ClinicalTrials.gov ID: NCT02784119
What this study is testing
- What it's testing
- The success of orthotopic liver transplantation (OLT) in treatment of liver malignancy and endstage liver disease has led to an increase in the gap between patients on waiting-lists and available liver grafts. In order to compensate for this scarcity, use of liver grafts harvested from extended criteria donors (ECD) has become more and more frequent.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old
- Candidate of liver transplantation
- With cirrhosis from any etiology
- Model For End-Stage Liver Disease (MELD) score \< 25
- Transplanted with a liver graft harvested from an extended criteria donor defined as presence of at least one of the following criteria:
You likely can't join if
- Complete portal vein thrombosis found during procedure
- Split liver graft
- Realisation of a bilio-enteric anastomosis
See the full eligibility criteria
- Age ≥ 18 years old
- Candidate of liver transplantation
- With cirrhosis from any etiology
- Model For End-Stage Liver Disease (MELD) score \< 25
- Transplanted with a liver graft harvested from an extended criteria donor defined as presence of at least one of the following criteria:
- Donor age \> 65 years old
- Intensive care unit stay \> 7 days
- BMI \> 30
- Natremia \> 155 mmol/L
- Aspartate aminotransferase (ASAT) \> 150 IU/mL
- Alanine aminotransferase (ALAT) \> 170 IU/mL
- Occurrence of a cardiac arrest before graft harvesting
- Proven biopsy macrosteathosis \> 30%
- Non-opposition from the patient Non
- Fulminant hepatitis
- Retransplantation
- Combined organ transplantation (kidney, pancreas, heart, lung)
- Non heart beating donor
- Complete portal vein thrombosis on preoperative imaging finding
- Complete portal vein thrombosis found during procedure
- Split liver graft
- Realisation of a bilio-enteric anastomosis
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
- Lyon, France
- Nice, France
- Rennes, France
- Toulouse, France
- Tours, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France; Lyon, France; Nice, France; Rennes, France; Toulouse, France; Tours, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.